No Data
Huaren Pharmaceutical (300110.SZ): The Active Pharmaceutical Ingredient for perphenazine has received a notification of approval for its listing application.
On January 21, Glonghui reported that Huaren Pharmaceutical (300110.SZ) announced that its wholly-owned subsidiary Anhui Hengxing Pharmaceutical Co., Ltd. received the "Chemical Raw Materials Approval Notice" issued by the National Medical Products Administration for the "Pirfenidone Active Pharmaceutical Ingredient". Pirfenidone is indicated for idiopathic pulmonary interstitial fibrosis. According to statistics from Yaozhi Network, the domestic consumption of Pirfenidone Active Pharmaceutical Ingredient in 2023 was 6.14 tons, an increase of 25.05% year-on-year.
Huaren Pharmaceutical (300110.SZ) subsidiary has obtained a medical instruments registration certificate.
Huaren Pharmaceutical (300110.SZ) announced that its wholly-owned subsidiary, Qingdao Huaren Medical Supplies Co., Ltd. received a notification from ShanDong...
Huaren Pharmaceutical (300110.SZ): Termination of the president position of Hong Liang.
On December 27, Glonghui reported that Huaren Pharmaceutical (300110.SZ) announced the convening of the sixth (extraordinary) meeting of the eighth Board of Directors on December 27, 2024, which reviewed and approved the "Proposal for the Dismissal of the Company's Chief Executive Officer." According to the needs of the company's Operation management, after the review by the Board of Directors' Nomination Committee, the Board of Directors agreed to dismiss Mr. Hong Liang from the position of Chief Executive Officer, with the dismissal taking effect from the date of approval by this Board of Directors meeting. Following the dismissal, Mr. Hong Liang will no longer hold any position within the company, and this dismissal will not adversely affect the normal operation of the company's daily production and Operation activities.
Huaren Pharmaceutical (300110.SZ): Currently, the company's export Business accounts for a small proportion.
On December 19, Gelonghui reported that Huaren Pharmaceutical (300110.SZ) stated on the investor interaction platform that, in terms of international business, the company's rubber stopper products have been exported to some countries in Europe and Asia. At the same time, the Pharmaceutical sector has successfully entered several pharmaceutical markets in Africa, Southeast Asia, and the Middle East. Currently, the company's export business occupies a relatively small proportion, and the company will actively expand its international business to fully explore new performance growth points.
Huaren Pharmaceutical Co., Ltd.'s (SZSE:300110) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Huaren Pharmaceutical (300110.SZ): Sodium bicarbonate Ringer's injection and sulfate terbutaline injection are proposed for selection in centralized procurement.
On December 13, Gelonghui reported that Huaren Pharmaceutical (300110.SZ) announced that the company and its wholly-owned subsidiary, Anhui Hengxing Pharmaceutical Co., Ltd., recently actively participated in the bidding for the tenth national centralized procurement organized by the National Organization for Pharmaceutical Joint Procurement Office. According to the results of the centralized procurement (Procurement Document No.: GY-YD2024-2) released by the procurement office, the company's product Sodium Bicarbonate Ringer's Injection and the product Sulfate Terbutaline Injection from its wholly-owned subsidiary Anhui Hengxing Pharmaceutical Co., Ltd. are proposed to be selected for this centralized procurement.
Investors Give Huaren Pharmaceutical Co., Ltd. (SZSE:300110) Shares A 30% Hiding
